Serum thrombopoietin level in various hematological diseases

Kensuke Usuki, Tomoyuki Tahara, Seiko Iki, Mitsue Endo, Mayumi Osawa, Koichi Kitazume, Takashi Kato, Hiroshi Miyazaki, Akio Urabe

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

To investigate the pathophysiological role of thrombopoietin (TPO) in thrombopoiesis, we measured its serum levels in 15 healthy individuals, 84 patients with various hematological diseases and 2 patients with liver cirrhosis using an enzyme immunoassay procedure. The TPO level was 0.84 ± 0.40 f mol/ml in normal individuals. TPO levels were considerably elevated in patients with myelosuppression after intensification chemotherapy of acute leukemia in complete remission (postchemotherapy group: n = 18; 18.46 ± 9.70) f mol/ml). When the data of normal individuals and the postchemotherapy group were combined, TPO levels were inversely correlated with the platelet count in this combined group. We compared these data of normal individuals and the postchemotherapy group with various hematological disease states. In aplastic anemia (n = 13; 16.03 ± 9.44 f mol/ml, acute lymphoblastic leukemia (n = 5; 10.36 ± 5.57 f mol/ml), malignant lymphoma (n = 6; 2.79 ± 2.27 f mol/ml), multiple myeloma (n = 3; 3.34 ± 0.20 f mol/ml and chronic lymphocytic leukemia (n = 21 1.71 ± 3.91 f mol/ml), the relationship of serum TPO levels and platelet counts was almost the same as in the combined group with normal individuals and the postchemotherapy group. However, the TPO levels were slightly higher in myeloproliferative disorders (n = 12; 1.99 ± 1.47 f mol/ml) and lower in acute myelogenous leukemia (n = 8; 2.27 ± 1.25 f mol/ml), hypoplastic leukemia (n = 3; 2.76 ± 2.23 f mol/ml, myelodysplastic syndrome (n = 2; 0.42 ± 0.60 f mol/ml), liver cirrhosis (n = 2; 1.50 ± 0.92 f mol/ml) and idiopathic thrombocytopenicpurpura (n = 12; 2.08 ± 1.41 f mol/ml), when compared to the regression line for the combined group with normal individuals and postchemotherapy group. These findings suggest that TPO might play an important role in regulation of the platelet count in normal and pathological conditions.

Original languageEnglish
Pages (from-to)558-565
Number of pages8
JournalStem Cells
Volume14
Issue number5
Publication statusPublished - 1996 Sep
Externally publishedYes

Fingerprint

Thrombopoietin
Hematologic Diseases
Serum
Platelet Count
Liver Cirrhosis
Leukemia
Thrombopoiesis
Myeloproliferative Disorders
Aplastic Anemia
Myelodysplastic Syndromes
B-Cell Chronic Lymphocytic Leukemia
Multiple Myeloma
Immunoenzyme Techniques
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Lymphoma
Drug Therapy

Keywords

  • Aplastic anemia
  • Idiopathic thrombocytopenic purpura
  • Leukemia
  • Liver cirrhosis
  • Malignant lymphoma
  • Multiple myeloma
  • Myelodysplastic syndrome
  • Myeloproliferative disorders
  • Myelosuppressive state
  • Serum level
  • Thrombopoietin

ASJC Scopus subject areas

  • Cell Biology

Cite this

Usuki, K., Tahara, T., Iki, S., Endo, M., Osawa, M., Kitazume, K., ... Urabe, A. (1996). Serum thrombopoietin level in various hematological diseases. Stem Cells, 14(5), 558-565.

Serum thrombopoietin level in various hematological diseases. / Usuki, Kensuke; Tahara, Tomoyuki; Iki, Seiko; Endo, Mitsue; Osawa, Mayumi; Kitazume, Koichi; Kato, Takashi; Miyazaki, Hiroshi; Urabe, Akio.

In: Stem Cells, Vol. 14, No. 5, 09.1996, p. 558-565.

Research output: Contribution to journalArticle

Usuki, K, Tahara, T, Iki, S, Endo, M, Osawa, M, Kitazume, K, Kato, T, Miyazaki, H & Urabe, A 1996, 'Serum thrombopoietin level in various hematological diseases', Stem Cells, vol. 14, no. 5, pp. 558-565.
Usuki K, Tahara T, Iki S, Endo M, Osawa M, Kitazume K et al. Serum thrombopoietin level in various hematological diseases. Stem Cells. 1996 Sep;14(5):558-565.
Usuki, Kensuke ; Tahara, Tomoyuki ; Iki, Seiko ; Endo, Mitsue ; Osawa, Mayumi ; Kitazume, Koichi ; Kato, Takashi ; Miyazaki, Hiroshi ; Urabe, Akio. / Serum thrombopoietin level in various hematological diseases. In: Stem Cells. 1996 ; Vol. 14, No. 5. pp. 558-565.
@article{780ca03b43fe46a886448bfebd81ab0c,
title = "Serum thrombopoietin level in various hematological diseases",
abstract = "To investigate the pathophysiological role of thrombopoietin (TPO) in thrombopoiesis, we measured its serum levels in 15 healthy individuals, 84 patients with various hematological diseases and 2 patients with liver cirrhosis using an enzyme immunoassay procedure. The TPO level was 0.84 ± 0.40 f mol/ml in normal individuals. TPO levels were considerably elevated in patients with myelosuppression after intensification chemotherapy of acute leukemia in complete remission (postchemotherapy group: n = 18; 18.46 ± 9.70) f mol/ml). When the data of normal individuals and the postchemotherapy group were combined, TPO levels were inversely correlated with the platelet count in this combined group. We compared these data of normal individuals and the postchemotherapy group with various hematological disease states. In aplastic anemia (n = 13; 16.03 ± 9.44 f mol/ml, acute lymphoblastic leukemia (n = 5; 10.36 ± 5.57 f mol/ml), malignant lymphoma (n = 6; 2.79 ± 2.27 f mol/ml), multiple myeloma (n = 3; 3.34 ± 0.20 f mol/ml and chronic lymphocytic leukemia (n = 21 1.71 ± 3.91 f mol/ml), the relationship of serum TPO levels and platelet counts was almost the same as in the combined group with normal individuals and the postchemotherapy group. However, the TPO levels were slightly higher in myeloproliferative disorders (n = 12; 1.99 ± 1.47 f mol/ml) and lower in acute myelogenous leukemia (n = 8; 2.27 ± 1.25 f mol/ml), hypoplastic leukemia (n = 3; 2.76 ± 2.23 f mol/ml, myelodysplastic syndrome (n = 2; 0.42 ± 0.60 f mol/ml), liver cirrhosis (n = 2; 1.50 ± 0.92 f mol/ml) and idiopathic thrombocytopenicpurpura (n = 12; 2.08 ± 1.41 f mol/ml), when compared to the regression line for the combined group with normal individuals and postchemotherapy group. These findings suggest that TPO might play an important role in regulation of the platelet count in normal and pathological conditions.",
keywords = "Aplastic anemia, Idiopathic thrombocytopenic purpura, Leukemia, Liver cirrhosis, Malignant lymphoma, Multiple myeloma, Myelodysplastic syndrome, Myeloproliferative disorders, Myelosuppressive state, Serum level, Thrombopoietin",
author = "Kensuke Usuki and Tomoyuki Tahara and Seiko Iki and Mitsue Endo and Mayumi Osawa and Koichi Kitazume and Takashi Kato and Hiroshi Miyazaki and Akio Urabe",
year = "1996",
month = "9",
language = "English",
volume = "14",
pages = "558--565",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "5",

}

TY - JOUR

T1 - Serum thrombopoietin level in various hematological diseases

AU - Usuki, Kensuke

AU - Tahara, Tomoyuki

AU - Iki, Seiko

AU - Endo, Mitsue

AU - Osawa, Mayumi

AU - Kitazume, Koichi

AU - Kato, Takashi

AU - Miyazaki, Hiroshi

AU - Urabe, Akio

PY - 1996/9

Y1 - 1996/9

N2 - To investigate the pathophysiological role of thrombopoietin (TPO) in thrombopoiesis, we measured its serum levels in 15 healthy individuals, 84 patients with various hematological diseases and 2 patients with liver cirrhosis using an enzyme immunoassay procedure. The TPO level was 0.84 ± 0.40 f mol/ml in normal individuals. TPO levels were considerably elevated in patients with myelosuppression after intensification chemotherapy of acute leukemia in complete remission (postchemotherapy group: n = 18; 18.46 ± 9.70) f mol/ml). When the data of normal individuals and the postchemotherapy group were combined, TPO levels were inversely correlated with the platelet count in this combined group. We compared these data of normal individuals and the postchemotherapy group with various hematological disease states. In aplastic anemia (n = 13; 16.03 ± 9.44 f mol/ml, acute lymphoblastic leukemia (n = 5; 10.36 ± 5.57 f mol/ml), malignant lymphoma (n = 6; 2.79 ± 2.27 f mol/ml), multiple myeloma (n = 3; 3.34 ± 0.20 f mol/ml and chronic lymphocytic leukemia (n = 21 1.71 ± 3.91 f mol/ml), the relationship of serum TPO levels and platelet counts was almost the same as in the combined group with normal individuals and the postchemotherapy group. However, the TPO levels were slightly higher in myeloproliferative disorders (n = 12; 1.99 ± 1.47 f mol/ml) and lower in acute myelogenous leukemia (n = 8; 2.27 ± 1.25 f mol/ml), hypoplastic leukemia (n = 3; 2.76 ± 2.23 f mol/ml, myelodysplastic syndrome (n = 2; 0.42 ± 0.60 f mol/ml), liver cirrhosis (n = 2; 1.50 ± 0.92 f mol/ml) and idiopathic thrombocytopenicpurpura (n = 12; 2.08 ± 1.41 f mol/ml), when compared to the regression line for the combined group with normal individuals and postchemotherapy group. These findings suggest that TPO might play an important role in regulation of the platelet count in normal and pathological conditions.

AB - To investigate the pathophysiological role of thrombopoietin (TPO) in thrombopoiesis, we measured its serum levels in 15 healthy individuals, 84 patients with various hematological diseases and 2 patients with liver cirrhosis using an enzyme immunoassay procedure. The TPO level was 0.84 ± 0.40 f mol/ml in normal individuals. TPO levels were considerably elevated in patients with myelosuppression after intensification chemotherapy of acute leukemia in complete remission (postchemotherapy group: n = 18; 18.46 ± 9.70) f mol/ml). When the data of normal individuals and the postchemotherapy group were combined, TPO levels were inversely correlated with the platelet count in this combined group. We compared these data of normal individuals and the postchemotherapy group with various hematological disease states. In aplastic anemia (n = 13; 16.03 ± 9.44 f mol/ml, acute lymphoblastic leukemia (n = 5; 10.36 ± 5.57 f mol/ml), malignant lymphoma (n = 6; 2.79 ± 2.27 f mol/ml), multiple myeloma (n = 3; 3.34 ± 0.20 f mol/ml and chronic lymphocytic leukemia (n = 21 1.71 ± 3.91 f mol/ml), the relationship of serum TPO levels and platelet counts was almost the same as in the combined group with normal individuals and the postchemotherapy group. However, the TPO levels were slightly higher in myeloproliferative disorders (n = 12; 1.99 ± 1.47 f mol/ml) and lower in acute myelogenous leukemia (n = 8; 2.27 ± 1.25 f mol/ml), hypoplastic leukemia (n = 3; 2.76 ± 2.23 f mol/ml, myelodysplastic syndrome (n = 2; 0.42 ± 0.60 f mol/ml), liver cirrhosis (n = 2; 1.50 ± 0.92 f mol/ml) and idiopathic thrombocytopenicpurpura (n = 12; 2.08 ± 1.41 f mol/ml), when compared to the regression line for the combined group with normal individuals and postchemotherapy group. These findings suggest that TPO might play an important role in regulation of the platelet count in normal and pathological conditions.

KW - Aplastic anemia

KW - Idiopathic thrombocytopenic purpura

KW - Leukemia

KW - Liver cirrhosis

KW - Malignant lymphoma

KW - Multiple myeloma

KW - Myelodysplastic syndrome

KW - Myeloproliferative disorders

KW - Myelosuppressive state

KW - Serum level

KW - Thrombopoietin

UR - http://www.scopus.com/inward/record.url?scp=0029744304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029744304&partnerID=8YFLogxK

M3 - Article

C2 - 8888496

AN - SCOPUS:0029744304

VL - 14

SP - 558

EP - 565

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 5

ER -